inhibitors of Aurora protein kinases; antiproliferative agents; melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopentanecarboxamide


Ontology type: sgo:Patent     


Patent Info

DATE

2010-08-03T00:00

AUTHORS

BINCH HAYLEY , MORTIMORE MICHAEL , DAVIS CHRIS , BOYALL DEAN , EVERITT SIMON , ROBINSON DANIEL , RAMAYA SHARN , FRAYSSE DAMIEN , STUDLEY JOHN , MILLER ANDREW , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , PINDER JOANNE

ABSTRACT

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/34", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/32", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "BINCH HAYLEY", 
        "type": "Person"
      }, 
      {
        "name": "MORTIMORE MICHAEL", 
        "type": "Person"
      }, 
      {
        "name": "DAVIS CHRIS", 
        "type": "Person"
      }, 
      {
        "name": "BOYALL DEAN", 
        "type": "Person"
      }, 
      {
        "name": "EVERITT SIMON", 
        "type": "Person"
      }, 
      {
        "name": "ROBINSON DANIEL", 
        "type": "Person"
      }, 
      {
        "name": "RAMAYA SHARN", 
        "type": "Person"
      }, 
      {
        "name": "FRAYSSE DAMIEN", 
        "type": "Person"
      }, 
      {
        "name": "STUDLEY JOHN", 
        "type": "Person"
      }, 
      {
        "name": "MILLER ANDREW", 
        "type": "Person"
      }, 
      {
        "name": "O'DONNELL MICHAEL", 
        "type": "Person"
      }, 
      {
        "name": "RUTHERFORD ALISTAIR", 
        "type": "Person"
      }, 
      {
        "name": "PINDER JOANNE", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/357161a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022093620", 
          "https://doi.org/10.1038/357161a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-199507060-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052340990", 
          "https://doi.org/10.2165/00002512-199507060-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35096075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049241198", 
          "https://doi.org/10.1038/35096075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014550555", 
          "https://doi.org/10.1038/nm1003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/343651a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015375932", 
          "https://doi.org/10.1038/343651a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/27208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053209158", 
          "https://doi.org/10.1038/27208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/jmn:19:3:275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016328080", 
          "https://doi.org/10.1385/jmn:19:3:275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051386685", 
          "https://doi.org/10.1038/sj.onc.1203598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35048096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051541099", 
          "https://doi.org/10.1038/35048096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02252107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020940579", 
          "https://doi.org/10.1007/bf02252107"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-08-03T00:00", 
    "description": "

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

", "endDate": "2026-11-25", "id": "sg:patent.US-7767672-B2", "name": "inhibitors of Aurora protein kinases; antiproliferative agents; melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopentanecarboxamide", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.422219.e", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-7767672-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-11-24T21:22", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/patent/patent_18.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7767672-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7767672-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7767672-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7767672-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

117 TRIPLES      15 PREDICATES      27 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7767672-B2 schema:about anzsrc-for:32
2 anzsrc-for:3211
3 anzsrc-for:34
4 schema:author Nbde4687eb90b4496bdc56063c7051485
5 schema:citation sg:pub.10.1007/bf02252107
6 sg:pub.10.1038/27208
7 sg:pub.10.1038/343651a0
8 sg:pub.10.1038/35048096
9 sg:pub.10.1038/35096075
10 sg:pub.10.1038/357161a0
11 sg:pub.10.1038/nm1003
12 sg:pub.10.1038/sj.onc.1203598
13 sg:pub.10.1385/jmn:19:3:275
14 sg:pub.10.2165/00002512-199507060-00007
15 schema:datePublished 2010-08-03T00:00
16 schema:description <p num="p-0001">The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.</p>
17 schema:endDate 2026-11-25
18 schema:name inhibitors of Aurora protein kinases; antiproliferative agents; melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopentanecarboxamide
19 schema:recipient grid-institutes:grid.422219.e
20 schema:sameAs https://app.dimensions.ai/details/patent/US-7767672-B2
21 schema:sdDatePublished 2022-11-24T21:22
22 schema:sdLicense https://scigraph.springernature.com/explorer/license/
23 schema:sdPublisher N2eb5f4a62ad54d6bb1e161a71aa6adad
24 sgo:license sg:explorer/license/
25 sgo:sdDataset patents
26 rdf:type sgo:Patent
27 N08c4a7d82f944ae2bf71671c5cd08d86 rdf:first Nac631ee4f338450fb27e8ff9e4c97a5a
28 rdf:rest N1612983e42054ceb9432adac25c0ed02
29 N112e2413041f4847b887e4387b9fa36d rdf:first N9e852ef311c94cf5ab9fd23b601eb66d
30 rdf:rest Nd3ec7f02e01f4df6b1c311d286eeaa56
31 N12897dc9e891496a862413f715e0c69d rdf:first Ne6c0703e24524ef8a22f515fc6d90a8e
32 rdf:rest N99a31604d8364205afaa0c6852930333
33 N13ce5a9ccda242709e17bdea715f9af1 schema:name MILLER ANDREW
34 rdf:type schema:Person
35 N1612983e42054ceb9432adac25c0ed02 rdf:first N5855fdde2ad4495ab0e4cd6fc9e49b25
36 rdf:rest N51d4583874eb43b6a62af4dee8090f31
37 N1dac867be68f486abc33906a1e6329be rdf:first N88014a8bec2b4c2f9af827186d077231
38 rdf:rest N9a563aea79cb4ad1b31c507e17b8db28
39 N2eb5f4a62ad54d6bb1e161a71aa6adad schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 N2f8e8500287c48f68ac4262f13e4cacf schema:name BINCH HAYLEY
42 rdf:type schema:Person
43 N38864922c3bf486a8204450599bc47c8 schema:name PINDER JOANNE
44 rdf:type schema:Person
45 N51d4583874eb43b6a62af4dee8090f31 rdf:first N88230c6395d64756b8b1dd5b8de4a2c0
46 rdf:rest N6ae1d58b6fad4a5397670f6e5e50be1f
47 N5855fdde2ad4495ab0e4cd6fc9e49b25 schema:name DAVIS CHRIS
48 rdf:type schema:Person
49 N6ae1d58b6fad4a5397670f6e5e50be1f rdf:first N9ce8c11cc0824e2ab9214d8f9a2c9604
50 rdf:rest N79d2855fdd044adb940d4fa860be80d2
51 N79d2855fdd044adb940d4fa860be80d2 rdf:first N8dfc611a14f240498a37d6200fedcdb5
52 rdf:rest N112e2413041f4847b887e4387b9fa36d
53 N88014a8bec2b4c2f9af827186d077231 schema:name STUDLEY JOHN
54 rdf:type schema:Person
55 N88230c6395d64756b8b1dd5b8de4a2c0 schema:name BOYALL DEAN
56 rdf:type schema:Person
57 N8dfc611a14f240498a37d6200fedcdb5 schema:name ROBINSON DANIEL
58 rdf:type schema:Person
59 N99a31604d8364205afaa0c6852930333 rdf:first N38864922c3bf486a8204450599bc47c8
60 rdf:rest rdf:nil
61 N9a563aea79cb4ad1b31c507e17b8db28 rdf:first N13ce5a9ccda242709e17bdea715f9af1
62 rdf:rest Ne5cfffdbffd3439094b23a352b2aa051
63 N9ce8c11cc0824e2ab9214d8f9a2c9604 schema:name EVERITT SIMON
64 rdf:type schema:Person
65 N9e852ef311c94cf5ab9fd23b601eb66d schema:name RAMAYA SHARN
66 rdf:type schema:Person
67 Nac631ee4f338450fb27e8ff9e4c97a5a schema:name MORTIMORE MICHAEL
68 rdf:type schema:Person
69 Nb8c2615f347d4f7fbf04f4d9a82209f5 schema:name O'DONNELL MICHAEL
70 rdf:type schema:Person
71 Nbde4687eb90b4496bdc56063c7051485 rdf:first N2f8e8500287c48f68ac4262f13e4cacf
72 rdf:rest N08c4a7d82f944ae2bf71671c5cd08d86
73 Ncecb95a7d62b4effb2237d64ad207975 schema:name FRAYSSE DAMIEN
74 rdf:type schema:Person
75 Nd3ec7f02e01f4df6b1c311d286eeaa56 rdf:first Ncecb95a7d62b4effb2237d64ad207975
76 rdf:rest N1dac867be68f486abc33906a1e6329be
77 Ne5cfffdbffd3439094b23a352b2aa051 rdf:first Nb8c2615f347d4f7fbf04f4d9a82209f5
78 rdf:rest N12897dc9e891496a862413f715e0c69d
79 Ne6c0703e24524ef8a22f515fc6d90a8e schema:name RUTHERFORD ALISTAIR
80 rdf:type schema:Person
81 anzsrc-for:32 schema:inDefinedTermSet anzsrc-for:
82 rdf:type schema:DefinedTerm
83 anzsrc-for:3211 schema:inDefinedTermSet anzsrc-for:
84 rdf:type schema:DefinedTerm
85 anzsrc-for:34 schema:inDefinedTermSet anzsrc-for:
86 rdf:type schema:DefinedTerm
87 sg:pub.10.1007/bf02252107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020940579
88 https://doi.org/10.1007/bf02252107
89 rdf:type schema:CreativeWork
90 sg:pub.10.1038/27208 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053209158
91 https://doi.org/10.1038/27208
92 rdf:type schema:CreativeWork
93 sg:pub.10.1038/343651a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015375932
94 https://doi.org/10.1038/343651a0
95 rdf:type schema:CreativeWork
96 sg:pub.10.1038/35048096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051541099
97 https://doi.org/10.1038/35048096
98 rdf:type schema:CreativeWork
99 sg:pub.10.1038/35096075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049241198
100 https://doi.org/10.1038/35096075
101 rdf:type schema:CreativeWork
102 sg:pub.10.1038/357161a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022093620
103 https://doi.org/10.1038/357161a0
104 rdf:type schema:CreativeWork
105 sg:pub.10.1038/nm1003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014550555
106 https://doi.org/10.1038/nm1003
107 rdf:type schema:CreativeWork
108 sg:pub.10.1038/sj.onc.1203598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051386685
109 https://doi.org/10.1038/sj.onc.1203598
110 rdf:type schema:CreativeWork
111 sg:pub.10.1385/jmn:19:3:275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016328080
112 https://doi.org/10.1385/jmn:19:3:275
113 rdf:type schema:CreativeWork
114 sg:pub.10.2165/00002512-199507060-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052340990
115 https://doi.org/10.2165/00002512-199507060-00007
116 rdf:type schema:CreativeWork
117 grid-institutes:grid.422219.e schema:Organization
 




Preview window. Press ESC to close (or click here)


...